WALTHAM, Mass.--(BUSINESS WIRE)-- NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the 9th Annual Needham Healthcare Conference taking place June 9-10, 2010 in New York, NY.
The NeurAxon presentation will be delivered on Wednesday, June 9, 2010 at 3:00pm Eastern Time at the New York Palace Hotel.
Dr. Bloch will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine.
About NeurAxon Inc.
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.
MacDougall Biomedical Communications
Chris Erdman, 508-647-0209 x14
KEYWORDS: United States North America Massachusetts New York
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical General Health